Updated MST report - target of $3.68 a share, page-49

I have always been interested in the science here, I have quite a few shares that I have in the bottom cupboard and I am now confident that the science is going to see this through - I can remember reading reviews from the parents of Rett Syndrome children being treated with trofinetide in the early trials and it gave me confidence that it worked with no (or little) side effects. The problem Neuren had over the past two years was the back ended deal that Richard Treagus (the CEO prior to Jon Pilcher) formulated with Acadia - the market hated it, because it was backended ... great thing is now - over two years later - we are AT THE BACK END! And this is just the start - Fragile-X and other targets for Neurens drugs have FIVE times the target market. And then, when all that is working - perhaps we can get back to treatment for Traumatic Brain Injury. Imagine if the NRL got wind of a drug that is "aspirin for the brain", There would be five to ten players per match popping our pills ;-)

Even without the latter - these drugs are going to help a lot of people - both financially and healthwise.

GLTAH.